Skip to main content

Table 3 New Phase II trials

From: Maintenance therapy in NSCLC: why? To whom? Which agent?

Trial/Author Comparison Comments References
NCT00867009 Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab as Maintenance IIIB or IV Nonquamous NSCLC ongoing, but not recruiting [39]
NCT00687297 Vandetanib (ZD6474)n With Docetaxel and Carboplatin Followed by Placebo or Vandetanib as Maintenance in IIIb, IV or Recurrent NSCLC ongoing, but not recruiting [39]
NCT01004250 Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Nonsquamous Advanced NSCLC currently recruiting [39]
NCT00425646 Maintenance Strategy of Gleevce® (Imatinib Mesylate) and Bevacizumab in Advanced, Non-Squamous, NSCLC Following Completion of First-Line Chemotherapy With Bevacizumab ongoing, but not recruiting [39]
NCT00766246 Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV NSCLC currently recruiting [39]